Multisystem inflammatory syndrome in adults after acute coronavirus disease 2019 in a Japanese woman: A case report. Issue 1 (January 2022)

• Record Type: Journal Article
• Authors: Miyamoto, Kyohei; Koizumi, Yusuke; Tamura, Shinobu; Nakashima, Tsuyoshi; Kobai, Kaori; Tanaka, Rikako; Shibata, Mami; Shima, Nozomu; Nemoto, Shigeki; Fukumoto, Nobu; Kato, Seiya
• Is Part Of: Journal of infection and chemotherapy. Volume 28:Issue 1(2022)
• Page Start: 99
• Page End: 102
• Publication Date: 2022-01
• Subjects: Multisystem inflammatory syndrome -- COVID-19 -- SARS-CoV-2; Multisystem inflammatory syndrome in adult MIS-A -- Severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 -- Multisystem inflammatory syndrome in adults MIS–A -- Coronavirus disease 2019 COVID-19 -- Reverse transcription-polymerase chain reaction RT-PCR -- Hemophagocytic lymphohistiocytosis HLH -- Severe fever with thrombocytopenia syndrome SFTS; Chemotherapy -- Periodicals; Infection -- Periodicals; Communicable diseases -- Chemotherapy -- Periodicals; 615.5805
• DOI: 10.1016/j.jiac.2021.09.014
• Languages: English
• ISSNs: 1341-321X

Abstract

Abstract: Multisystem inflammatory syndrome in adults (MIS-A) is a rare and emerging syndrome after coronavirus disease 2019 (COVID-19). To the best of our knowledge, Japanese cases of MIS-A are rarely reported. Here, we describe a case of MIS-A in a 44-year-old Japanese woman presenting with multiorgan dysfunction (i.e., cardiovascular and mucocutaneous involvement) and markedly elevated inflammatory markers 2 weeks after recovery from COVID-19. Treatment with intravenous immunoglobulins and corticosteroids resolved her symptoms. On the 13th day, she was discharged from the hospital with no recurrences on follow-up. This study highlights the importance of recognizing this emerging syndrome when treating patients with multiorgan dysfunction after COVID-19.